The RRT technologies and nephrology practices on which the FDA guidance was based have evolved significantly over the last several years, as the vancomycin example above illustrates. This evolution has created huge knowledge deficits in how to dose drugs appropriately. When we recently co-authored a renal drug dosing text we were concerned to find that CRRT drug dosing studies have been conducted for <20% of currently used drugs. 6 Furthermore, pharmacokinetic studies in newer hybrid RRTs, including slow lowefficiency dialysis and extended daily dialysis, have been conducted for <1% of marketed drugs. Importantly, dosing recommendations for one form of RRT usually cannot be applied to other forms of RRT. The cumulative consequence of all of these RRT advances is that clinicians now have dangerously little information to guide the safe and effective dosing of the vast majority of drugs used in patients requiring RRT. In this context, the vancomycin example above exemplifies a larger problem. Clinicians are very familiar with and knowledgeable about vancomycin, and it has been used for more than 50 years. Were it not for the fact that we can easily measure vancomycin serum concentrations, we would probably not even appreciate how significantly the changes in RRT have influenced vancomycin clearance. More concerning is the fact that clinicians are faced with dosing hundreds of other drugs that have been studied far less than vancomycin and for which serum concentrations cannot be measured in a clinical laboratory. The effects that the recent changes in RRT have had on the pharmacokinetics of these agents are also obviously unknown. Our greatest concern is that there currently is no clear plan to ensure the development of this knowledge, which is critical for the safe and effective use of drugs (both current and future) during RRT. With this in mind, we make the following suggestions to bridge this knowledge gap for pharmacotherapy in patients receiving RRT.
recommendations
The 1998 FDA guidance and subsequent preliminary concept paper 7 provide patients, with the dose often given during the last 60-90 minutes of hemodialysis because only a small amount was removed by the dialysis procedure. In marked contrast, contemporary hemodialyzers are highly permeable and quite capable of clearing significant amounts of vancomycin. Today, a 1,000-mg dose of vancomycin once weekly during hemodialysis will almost certainly result in significant underdosing in an adult with renal failure. Similarly, contemporary continuous cycling peritoneal dialysis, using more rapid exchanges and "cyclers" to make these dialysate exchanges, also probably requires different vancomycin dosing regimens than those used with continuous ambulatory peritoneal dialysis. Even original articles describing vancomycin dosing in continuous renal replacement therapy (CRRT) used less efficient hemodiafilters and lower dialysate flow rates than those used today. Consequently, although few data are available, the vancomycin doses needed for higher-volume CRRT are clearly greater than in the past.
Whereas advances in RRT technology and clinical practice have necessitated changes in how vancomycin is dosed, the most recent FDA-approved vancomycin package insert that we could identify makes no mention of dosing recommendations for peritoneal dialysis or CRRT. 5 Indeed, drug clearance data for hemodialysis or CRRT are not mentioned, and only a recommendation of 1,000 mg every 7-10 days for anuric patients is made. 5 Clearly, strict adherence to the current vancomycin package insert while treating patients with contemporary RRT would systematically underdose patients and probably jeopardize, rather than enhance, patient safety.
problems. 3 Appropriate drug dosing is thus a major challenge in these patients, and clinicians look to the research literature to provide guidance. Unfortunately, there is a paucity of published data that can be applied to these dosing situations, and the current, 11-year-old US Food and Drug Administration (FDA) Guidance for Pharmacokinetics in Patients with Impaired Renal Function 4 has gradually been made obsolete as RRT technology and clinical practices have evolved.
The types and use of RRT have changed dramatically over the last several years, mainly as a result of technological advances. The RRT of the 1980s and 1990s bears little resemblance to today's RRT ( Table 1) . In nearly all cases, the changes in RRT have resulted in greater drug clearances. The clinical dilemma caused by these advances is that the pharmacokinetic studies that formed the basis for many of the drug dosing recommendations used today were derived in the 1980s and 1990s using RRT techniques and technologies that are no longer used in current practice.
the example of vancomycin
Vancomycin is commonly used in patients requiring RRT, usually because of the high rate of gram-positive infections in these patients. Because vancomycin is cleared primarily by the kidneys, dosing of this drug must be adjusted in patients receiving RRT. In this setting, serum concentration monitoring can be used to guide these dosing decisions. Early pharmacokinetic studies conducted in the 1980s suggested that vancomycin was not significantly cleared by hemodialysis. Consequently, 1,000 mg of vancomycin was dosed once weekly in hemodialysis CRRT pharmacokinetic studies should also be performed in pediatric patients using pediatric hemofilters. Although the above suggestions will greatly improve rational drug dosing during CRRT in adults, children with AKI are typically forced to use adult CRRT equipment and adult-sized hemofilters because pediatricspecific equipment is often unavailable. The use of such oversized filters often results in significant distortions in drug pharmacokinetics, particularly in smaller children and infants, and can thus greatly affect both drug efficacy and safety.
Barriers and potential solutions
The current FDA guidance recommends that pharmacokinetic studies be conducted solely in hemodialysis for selected drugs likely to be cleared by hemodialysis. In light of the markedly increased usage of CRRT, the addition of a request for CRRT drug clearance data and dosing recommendations to the 2008 FDA preliminary concept paper 7 would significantly improve the safety and efficacy of drugs used in critically ill adults and children with AKI. Ideally, this information would be generated from clinical trials conducted in critically ill adult and pediatric patients. when total effluent rates are used to generate CRRT drug clearance estimates. Given that CVVHD is the most widely used type of CRRT, pharmacokinetic data from CVVHD would have the broadest applicability to assist clinicians in determining appropriate drug dosing during any type of CRRT with conventional effluent rates.
The dose of delivered therapy for CRRT pharmacokinetic studies should be 35 ml/h/ kg (or 2,000 ml/h/1.73 m 2 ). This suggestion is evidence based, because this dose of CRRT has been demonstrated to provide superior patient outcomes in adults. 9 Although other important trials have shown that lower effluent rates are associated with similar patient outcomes, 10 RRT doses in this range are currently used widely throughout the world in both adult and pediatric patients. Although some centers use higher or lower rates than this, this rate represents a compromise that will have applicability to most CRRT practices worldwide.
CRRT pharmacokinetic studies should be performed with the most commonly used hemofilters in contemporary practice. There is a wide variety of CRRT hemofilters, and each has different effects on transmembrane drug clearance (from data in our laboratory and others). Thus, to ensure the broadest applicability in practice, CRRT pharmacokinetic studies should be performed using two different CRRT hemoappropriate direction for identifying which drugs should have pharmaco kinetic studies conducted in patients with renal disease. Since then, however, both the treatments of acute kidney injury (AKI) and chronic kidney disease and dialysis technologies have changed considerably. Based on these advances, we suggest the following approaches.
Hemodialysis. For drugs likely to be removed by hemodialysis, all hemodialysis pharmacokinetic studies should be conducted using a standardized "dose" of hemodialysis using a kT/V urea of ≥1.2. In the current guidance, the suggested hemodialysis pharmacokinetic studies do not specify dialysis dose. However, the most recent National Kidney Foundation-Kidney Disease Outcomes Quality Initiative guidelines 8 identify the dose of hemodialysis that is associated with optimal patient outcomes as a kT/V urea of ≥1.2.
All hemodialysis pharmacokinetic studies should use hemodialyzers of a standardized surface area and ultrafiltration coefficient. Hemodialysis pharmaco kinetic studies should be conducted with highpermeability hemodialysis membranes, as are used in the majority of contemporary practice.
All hemodialysis pharmacokinetic studies should be performed in pediatric patients using pediatric hemodialyzers. Such studies should specify the dialyzer surface area (absolute and relative to patient surface area), as well as the hemodialysis dose (kT/V urea ) used. 
